Señales en vivo de 950210.KS | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 abr 2024 @ 20:38):

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific...

Stats
Volumen de hoy	767.00
Volumen promedio	56 726.00
Capitalización de mercado	483.77B
EPS	KRW-238.40 ( 2023-03-31 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW13.69 (0.17%)

Volumen Correlación

Largo: 0.03 (neutral)

Corto: -0.12 (neutral)

Signal:(57.334) Neutral

Prestige BioPharma Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Prestige BioPharma Correlación - Moneda/Commodity

0.39
( neutral )

0.29
( neutral )

0.26
( neutral )

0.04
( neutral )

-0.21
( neutral )

-0.05
( neutral )

Prestige BioPharma Finanzas

Annual	2022
Ingresos:	KRW161.84M
Beneficio Bruto:	KRW-11.50B (-7 103.88 %)
EPS:	KRW292.58

FY	2022
Ingresos:	KRW161.84M
Beneficio Bruto:	KRW-11.50B (-7 103.88 %)
EPS:	KRW292.58

FY	2022
Ingresos:	KRW0
Beneficio Bruto:	KRW0 (0.00 %)
EPS:	KRW-3 519.20

FY	2021
Ingresos:	KRW0.00
Beneficio Bruto:	KRW0.00 (0.00 %)
EPS:	KRW-866.40

Financial Reports:

No articles found.

Prestige BioPharma

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.